厄贝沙坦和怡开联合治疗2型糖尿病肾病的临床观察

Study on Therapeutic Effect of Irbesartan combined with Yikai on Diabetic Nephropathy of Type 2 Diabetes

目的比较单用厄贝沙坦及厄贝沙坦联合怡开(胰激肽原酶肠溶片)治疗2型糖尿病肾病(DN)的疗效。方法2型糖尿病DN患者64例,随机分为两组,对照组单用厄贝沙坦治疗,治疗组厄贝沙坦联合怡开,共12周。比较治疗前后24h尿白蛋白排泄率(UAER)、血肌酐(CR)﹑血压(BP)的变化。结果两组用药均可使2型糖尿病DN患者24h尿白蛋白排泄率下降(P<0.01),血压下降(P<0.01),但治疗组在降低尿白蛋白的排泄作用更明显(P<0.05)。结论对于DN患者,联合应用厄贝沙坦和怡开,比单用厄贝沙坦更有效减少2型糖尿病DN白蛋白尿,延缓DN患者病情。

Objective To observe the effects of combined use of irbesartan with Yikai（pancreatic kininogenase tablets） on the treatment of diabetic nephropathy of type 2 diabetes.Methods 64 patients with diabetic nephropa-thy of type 2 diabetes were divided randomly into two groups：control group and treatment group.The control group took irbesartan for 12 weeks,the treatment group took irbesartan and Yikai for 12 weeks.Urinary albumin excretion rate（UAER）,creatinine（CR）,blood pressure（BP） were compared between two groups before treatment and after treatment.Results Significant decrease was detected in UAER（P〈0.01）,significant decrease was detected in blood pressure（P〈0.01）;the combination treatment group＇s decrease especially in UAER was more significant（P〈0.05）.Conclusion Combined administration of Yikai with irbesartan may reduce proteinuria in diabetic nephropathy in shortterm,and lower the medicalburden.